Autoimmune Liver Disease — Written Clinical Reasoning

SAQ 1 — AIH-PBC overlap in a 54-year-old woman (15 marks, 30 minutes)

Prompt: Outline your assessment, the diagnostic reasoning, the integrated management plan addressing each problem, and the communication framework. Justify each decision with reference to evidence. [1]

Model Answer

Step 1 — The diagnostic synthesis (4 marks): [1]

This woman has an AIH-PBC overlap syndrome. The reasoning: she has features of BOTH diseases. For PBC, she has a cholestatic LFT pattern (ALP and gamma-GT disproportionately raised), a positive AMA at a high titre, a raised IgM, and the florid duct lesion on biopsy. For AIH, she has a hepatocellular component (the ALT of 180), a markedly raised IgG, positive ANA and SMA, and interface hepatitis with a plasma-cell infiltrate on biopsy. [1]

I would apply the Paris criteria for AIH-PBC overlap: two of three AIH features (interface hepatitis; ALT two to five times the upper limit; IgG two times the upper limit OR positive ANA/SMA) AND two of three PBC features (AMA positive; compatible biopsy; raised IgM). She meets all three AIH criteria (interface hepatitis, ALT raised though at the lower bound, IgG raised though I would confirm the ratio, ANA/SMA positive) and all three PBC criteria (AMA positive, florid duct lesion, raised IgM) [7]. The diagnosis is therefore definite overlap. The normal ultrasound excludes biliary obstruction. An MRCP is not required (her ducts are normal and she has no IBD to raise PSC), but I would send an IgG4 to exclude IgG4-sclerosing cholangitis, which can coexist with a cholestatic picture and is steroid-responsive.

The IAIHG position statement (Boberg 2011) cautions that overlap is partly a research concept and that patients should be treated for their predominant feature, but in this case the features of both diseases are clearly present and a combined strategy is justified [7].

Step 2 — The problem list (2 marks): [1]

1. AIH-PBC overlap syndrome with cholestatic and hepatocellular components — the central problem.
2. Cirrhosis or pre-cirrhosis — the jaundice (bilirubin 75) and the low albumin suggest synthetic dysfunction; I would stage with elastography (FibroScan) and review the biopsy for fibrosis.
3. Pruritus — a major quality-of-life issue; needs active management.
4. Osteoporosis risk — from the cholestasis AND the corticosteroids I will need to use.
5. Fat-soluble vitamin deficiency — likely given the cholestasis and jaundice.
6. Portal hypertension and HCC surveillance — once cirrhosis is confirmed.
7. Psychosocial impact and communication — a complex chronic diagnosis with lifelong therapy. [1]

Step 3 — The integrated management plan (6 marks): [1]

Pillar 1 — Ursodeoxycholic acid (UDCA) for the PBC component: I would start UDCA at 13 to 15 mg/kg/day in divided doses, first-line for all stages of PBC. The 1994 Lindor NEJM trial showed UDCA slows histological progression and reduces the need for transplant in PBC [2]. This is non-negotiable first-line therapy and will be continued lifelong.

Pillar 2 — Immunosuppression for the AIH component: I would add prednisolone 0.5 to 1 mg/kg/day (typically 40 to 60 mg daily) plus azathioprine 1 to 2 mg/kg/day. Critically, I would check thiopurine methyltransferase (TPMT) activity before starting azathioprine — TPMT deficiency causes fatal myelosuppression [5]. I would monitor the full blood count weekly for the first month, then monthly. In a patient without cirrhosis I would consider budesonide (a first-pass corticosteroid) to spare the steroid side effects, but given her possible cirrhosis (low albumin, jaundice) I would use prednisolone, as budesonide is ineffective in cirrhosis due to portosystemic shunting.

Pillar 3 — Staging and surveillance: FibroScan to stage fibrosis; upper GI endoscopy for variceal surveillance if cirrhosis is confirmed; baseline DEXA for bone density; six-monthly ultrasound plus alpha-fetoprotein once cirrhosis is confirmed; annual fat-soluble vitamin levels. [1]

Pillar 4 — Symptom control: For the pruritus, cholestyramine first-line (given separately from UDCA by at least 2 to 4 hours), then rifampicin 150 to 300 mg twice daily with liver function monitoring, then opioid antagonists (naltrexone) or sertraline. For the fatigue, there is no specific therapy — I would address sleep, mood and deconditioning, and exclude other causes (anaemia, hypothyroidism, vitamin D deficiency). [1]

Pillar 5 — Bone and nutritional health: Calcium and vitamin D supplementation; a bisphosphonate if the DEXA shows osteoporosis. Replace vitamins A, D, E and K as needed. For the corticosteroids, add bone protection, monitor blood glucose and blood pressure, and consider a PPI for gastroprotection. [1]

Pillar 6 — Second-line consideration: If her biochemistry does not normalise on UDCA plus immunosuppression, I would consider adding obeticholic acid for the PBC component — but ONLY if her cirrhosis is compensated (Child-Pugh A). OCA is contraindicated in decompensated (Child-Pugh B and C) cirrhosis because it can precipitate liver failure [3].

Step 4 — Communication (3 marks): [1]

I would explain the diagnosis in plain language: her immune system is attacking both the bile ducts and the liver cells, which is why she has features of two diseases, and the treatment needs to address both. I would explain that the UDCA is for the bile duct disease (lifelong), and the prednisolone and azathioprine are for the immune attack on the liver cells (at least 24 months before considering withdrawal). I would be honest about the chronicity, the surveillance burden, the corticosteroid side effects, and the transplant possibility if the disease progresses. I would involve the GP, the dietitian, the physiotherapist (for deconditioning), and a hepatology nurse specialist. I would document the shared decisions and review them as the biochemistry responds. [1]

SAQ 2 — PSC with a new dominant stricture: the cholangiocarcinoma question (10 marks, 20 minutes)

Prompt: A 38-year-old man with a 12-year history of ulcerative colitis and a 5-year history of primary sclerosing cholangitis presents with a 6-week history of progressive painless jaundice, weight loss of 5 kg, and worsening pruritus. His CA 19-9 has risen from 40 to 320 U/mL. A recent MRCP shows a new dominant stricture in the common hepatic duct with upstream dilatation. Outline your assessment, the differential, the investigation strategy, and the management plan. [1]

Model Answer

Step 1 — The clinical synthesis and the differential (2 marks): [1]

This is a classic and dangerous presentation: a PSC patient with a new dominant stricture, progressive jaundice, weight loss and a rising CA 19-9. The differential for a dominant stricture in PSC is: (1) a benign PSC stricture (the most common); (2) cholangiocarcinoma (the feared diagnosis — lifetime risk 5 to 20 percent in PSC, with 30 to 50 percent of cases diagnosed within the first year of PSC); and (3) an impacted stone or sludge. The weight loss and the rising CA 19-9 raise the index of suspicion for cholangiocarcinoma, though CA 19-9 is neither sensitive nor specific and can be elevated in cholestasis and cholangitis [4].

Step 2 — The investigation strategy (4 marks): [1]

I would arrange the following in parallel: [1]

1. ERCP with balloon dilatation and brush cytology — the central investigation and the therapeutic intervention. Balloon dilatation relieves the obstruction and the jaundice; brushings of the stricture provide the pathological assessment. Brushings have limited sensitivity (around 20 to 40 percent for cholangiocarcinoma) but are the standard first test. If the brushings are non-diagnostic and suspicion persists, I would arrange cholangioscopy with targeted biopsy (which has higher sensitivity) and/or a PET-CT (which can differentiate malignant from benign strictures by metabolic activity).
2. Cross-sectional imaging — a contrast CT of the chest, abdomen and pelvis (or MRI) for staging if cholangiocarcinoma is confirmed, and to assess for vascular invasion, lymphadenopathy and metastases.
3. Exclusion of cholangitis — blood cultures and a full infection screen; if there is evidence of cholangitis, start broad-spectrum antibiotics (e.g. piperacillin-tazobactam) before the ERCP, because the obstruction predisposes to bacterial cholangitis.
4. Referral to the multidisciplinary team — hepatology, hepatobiliary surgery, oncology and radiology — because the distinction between a benign and a malignant stricture, and the staging, dictate whether the patient is a candidate for resection, liver transplant (in selected unresectable hilar CCA cases), or palliative biliary drainage. [1]

Step 3 — The management plan (3 marks): [1]

If the stricture is benign, the management is ERCP with dilatation ± stenting, continued surveillance (annual MRI/MRCP plus CA 19-9, annual colonoscopy for colorectal cancer in his IBD), and management of the pruritus (cholestyramine then rifampicin). [1]

If the stricture is malignant (cholangiocarcinoma), the management depends on the stage and the location: distal CCAs may be resectable (pancreaticoduodenectomy/Whipple); perihilar CCAs (Klatskin) are often unresectable; in selected unresectable perihilar CCAs without metastases, liver transplant is an option in some protocols (the Mayo protocol with neoadjuvant chemoradiation). For metastatic disease, the management is palliative — biliary drainage, systemic chemotherapy (gemcitabine plus cisplatin), and symptom control. [1]

I would NOT give high-dose ursodeoxycholic acid (the 2009 trial showed harm in PSC) and I would NOT give corticosteroids (PSC is not steroid-responsive, and steroids would mask rather than treat a malignancy). [1]

Step 4 — Communication (1 mark): [1]

I would communicate the finding and the concern honestly — that a new dominant stricture with weight loss and a rising CA 19-9 raises the possibility of cholangiocarcinoma, that the ERCP and the brushings will give us the answer, and that the multidisciplinary team is involved. I would address the anxiety, the uncertainty, and the timeline, and I would arrange close follow-up and a support structure for the patient and his family. [1]